Bellance N, Furt F, Melser S, Lalou C, Thoraval D, Maneta-Peyret L
Int J Mol Sci. 2020; 21(4).
PMID: 32075281
PMC: 7072979.
DOI: 10.3390/ijms21041317.
Khan S, Danishuddin M, Varshney B, Lal S, Khan A
PLoS One. 2012; 7(12):e51850.
PMID: 23251640
PMC: 3522591.
DOI: 10.1371/journal.pone.0051850.
Bristow M
West J Med. 1983; 139(3):369-71.
PMID: 18749444
PMC: 1021531.
Morre D, Kim C, Paulik M, Morre D, Faulk W
J Bioenerg Biomembr. 1997; 29(3):269-80.
PMID: 9298712
DOI: 10.1023/a:1022414228013.
Creasey W
Br J Cancer. 1981; 44(6):921-4.
PMID: 7326201
PMC: 2010863.
DOI: 10.1038/bjc.1981.293.
Toxicity of liposomal N-acyl daunorubicins to L929 cells in culture.
Bard D, Knight C, Page-Thomas D
Br J Cancer. 1982; 45(5):783-5.
PMID: 7082560
PMC: 2011017.
DOI: 10.1038/bjc.1982.121.
Synthesis of adriamycin-coupled polyglutaraldehyde microspheres and evaluation of their cytostatic activity.
Tokes Z, Rogers K, Rembaum A
Proc Natl Acad Sci U S A. 1982; 79(6):2026-30.
PMID: 6804952
PMC: 346115.
DOI: 10.1073/pnas.79.6.2026.
Toxic effects of adriamycin on the central nervous system. Ultrastructural changes in some circumventricular organs of the mouse after intravenous administration of the drug.
Bigotte L, Olsson Y
Acta Neuropathol. 1983; 61(3-4):291-9.
PMID: 6650142
DOI: 10.1007/BF00692000.
Mechanisms of action of intravesical treatment. Effect on the ABH surface antigens of urothelial cells.
Jakse G, Hofstadter F
Cancer Chemother Pharmacol. 1983; 11 Suppl:S74-8.
PMID: 6640839
Inhibition of plasma membrane NADH dehydrogenase by adriamycin and related anthracycline antibiotics.
Sun I, Crane F, Low H, Grebing C
J Bioenerg Biomembr. 1984; 16(3):209-21.
PMID: 6598803
DOI: 10.1007/BF00751050.
Adriamycin inhibits PTH-mediated but not PGE2-mediated stimulation of cyclic AMP formation in isolated bone cells.
Kohler G, Shen V, Peck W
Calcif Tissue Int. 1984; 36(3):279-84.
PMID: 6088009
DOI: 10.1007/BF02405331.
Lysosomal alterations in heart and liver of mice treated with doxorubicin.
Gebbia N, Leto G, Gagliano M, Tumminello F, Rausa L
Cancer Chemother Pharmacol. 1985; 15(1):26-30.
PMID: 4006046
DOI: 10.1007/BF00257289.
Melphalan-induced enhancement of tumor cell immunostimulatory capacity as a mechanism for the appearance of potent antitumor immunity in the spleen of mice bearing a large metastatic MOPC-315 tumor.
Bocian R, Dray S, Ben-Efraim S, Mokyr M
Cancer Immunol Immunother. 1985; 20(1):61-8.
PMID: 3933817
PMC: 11038149.
DOI: 10.1007/BF00199775.
Anthracycline-induced inhibition of membrane permeability functions dependent on metabolic energy.
Croce A, Prosperi E, Supino R, Bottiroli G
Br J Cancer. 1986; 54(6):943-50.
PMID: 3801290
PMC: 2001592.
DOI: 10.1038/bjc.1986.265.
Are reduced quinones necessarily involved in the antitumour activity of quinone drugs?.
Butler J, Hoey B
Br J Cancer Suppl. 1987; 8:53-9.
PMID: 3307874
PMC: 2149497.
Doxorubicin effects on contractile structures and molecules.
Colombo R, Milzani A, NECCO A, Vailati G
Cytotechnology. 1990; 3(1):9-19.
PMID: 1366656
DOI: 10.1007/BF00365261.
